3 Things to Watch in Merck's Upcoming Earnings

Merck has struggled with the patent cliff's hit on its sales lately, but can this top pharma stock bounce back with earnings on tap?

Jan 31, 2014 at 6:30PM

Earnings season has been a mixed bag for big pharma so far this month, but the industry has a chance to score a big victory for investors when Merck (NYSE:MRK) reports its quarterly results next Wednesday. Merck has struggled with the patent cliff, like many of the top names in big pharma recently, and top drugs such as the diabetes-fighting duo Januvia and Janumet have struggled to gain significant sales growth.

Still, Merck has plenty going for its stock as one of the biggest names in health care. The firm's developmental cancer therapy, MK-3475, in particular has garnered high praise from analysts. Merck recently filed MK-3475 for regulatory approval in the U.S. as a melanoma treatment, and analysts project that the drug could one day garner up to $3 billion in annual sales if Merck can score approvals for more uses of the therapy.

MK-3475's development is one thing to watch in Merck's upcoming performance report, but what else do you need to keep an eye on? Find out what to watch from this top big pharma stock in the video below, as Motley Fool contributor Dan Carroll goes through the three most important things investors need to look out for in Merck's earnings -- and how they could make or break this stock heading into 2014.

Is Merck the right dividend for you?
Merck and other big pharma stocks have emerged as some of the top dividend-paying stocks on the market, but any great investor knows the power of diversifying your portfolio. If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information